. Author manuscript; available in PMC: 2013 Oct 9.

Published in final edited form as: Biol Blood Marrow Transplant. 2009 Sep;15(9):1108–1115. doi: 10.1016/j.bbmt.2009.05.015

Table 4.

Results from the Multivariate Analysis of Factors Associated with Overall Survival (OS), Relapse-Free Survival (RFS), Treatment-Related Mortality (TRM), and Graft-versus-Host Disease (GVHD) after Unrelated Donor HSCT

	Transplant-Related Mortality
	RH	95%CI	P-Value
aGVHD II-IV	12.3	3.63-41.7	<.001
LC30^*	0.88	0.77-1.00	<.05
G-CSF	3.42	1.21-9.68	.02
Relapse-free survival
aGVHD II-IV	0.39	0.18-0.82	.014
LC30^*	3.42	1.07-10.9	.036
CD34 dose^*	0.95	0.91-0.99	.024
Overall survival
aGVHD II-IV	0.19	0.09-0.40	<.001
Platelets D +30^*	1.10	1.04-1.17	.006
CD34 dose^*	0.94	0.90-0.98	.002

LC30 indicates day 30 absolute lymphocyte count; platelets, day 30 platelet count; CD34 dose, CD34⁺ cell dose in graft (× 10⁶/kg); aGVHD; acute graft-versus-host disease; G-CSF; granulocyte-colony stimulating factor administration postgraft; HSCT, hematopoietic stem cell transplantation.

Analyzed as continuous variables.